What does CUSIP 046513206 represent in this 13F holders report?

CUSIP 046513206 is the security identifier for ATRA - Atara Biotherapeutics, Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held ATRA - Atara Biotherapeutics, Inc. - Common Stock in Q4 2025?

40 institutional investors reported ATRA - Atara Biotherapeutics, Inc. - Common Stock for Q4 2025. Use the holders table for investor-level position and value details.

Atara Biotherapeutics, Inc. - Common Stock (ATRA)

CUSIP: 046513206

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class: Equity / Common Stock
Shares outstanding: 7,230,838
Total 13F shares: 2,049,655
Share change: +166,547
Total reported value: $37,062,796
Price per share: $18.09
Number of holders: 40
Value change: +$3,113,209
Number of buys: 19
Number of sells: 9

Quarterly Holders Quick Answers

What is CUSIP 046513206?
CUSIP 046513206 identifies ATRA - Atara Biotherapeutics, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2026
Previous quarter: Q3 2025

Recent filing periods for CUSIP 046513206:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of ATRA - Atara Biotherapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Redmile Group, LLC	13D/G 3/4/5 13F	Director · Company	9.9%	751,223	$10,764,875	+$659,400	12 Nov 2025	13D/G 3/4/5 13F
Adiumentum Capital Fund I LP	3/4/5 13D/G	Director, Other*, 10%+ Owner	20% from 13D/G	1,586,588 mixed-class rows	$10,487,308	—	16 May 2025	3/4/5 13D/G
EcoR1 Capital, LLC	13D/G 13F	Company	9.9%	715,853	$10,258,030	$0	30 Sep 2025	13D/G 13F
Panacea Innovation Ltd	13D/G	Panacea Venture Healthcare Fund II, L.P.	9.5%	550,000	$4,180,000	$0	30 Jan 2025	13D/G
VANGUARD GROUP INC	13F	Company	2.8%	203,438	$2,915,266	—	30 Sep 2025	13F
MARSHALL WACE, LLP	13F	Company	1.6%	115,796	$1,659,357	—	30 Sep 2025	13F
BlackRock, Inc.	13F	Company	0.97%	69,833	$1,000,706	—	30 Sep 2025	13F
MACKENZIE FINANCIAL CORP	13F	Company	0.88%	63,816	$914,483	—	30 Sep 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.84%	60,526	$867,499	—	30 Sep 2025	13F
ACADIAN ASSET MANAGEMENT LLC	13F	Company	0.78%	56,416	$807,000	—	30 Sep 2025	13F
STALEY CAPITAL ADVISERS INC	13F	Company	0.69%	50,000	$716,500	—	30 Sep 2025	13F
Pascal Touchon	3/4/5	Director	1.1%	77,955	$589,339	—	10 Jun 2025	3/4/5
MORGAN STANLEY	13F	Company	0.5%	35,938	$514,991	—	30 Sep 2025	13F
Eric J. Hyllengren	3/4/5	Former EVP, CFO & COO	— mixed-class rows	58,887 mixed-class rows	$393,448	—	31 Mar 2025	3/4/5
GSA CAPITAL PARTNERS LLP	13F	Company	0.36%	26,213	$376,000	—	30 Sep 2025	13F
STATE STREET CORP	13F	Company	0.35%	25,253	$361,875	—	30 Sep 2025	13F
JANE STREET GROUP, LLC	13F	Company	0.31%	22,060	$316,120	—	30 Sep 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.26%	18,936	$271,353	—	30 Sep 2025	13F
Carol Giltner Gallagher	3/4/5	Director	0.46%	33,012	$249,570	—	10 Jun 2025	3/4/5
UBS Group AG	13F	Company	0.24%	17,268	$247,451	—	30 Sep 2025	13F
FMR LLC	13F	Company	0.24%	17,156	$245,845	—	30 Sep 2025	13F
Cambridge Investment Research Advisors, Inc.	13F	Company	0.24%	17,109	$245,000	—	30 Sep 2025	13F
Quadrature Capital Ltd	13F	Company	0.23%	16,542	$236,881	—	30 Sep 2025	13F
GLOBEFLEX CAPITAL L P	13F	Company	0.21%	15,458	$221,513	—	30 Sep 2025	13F
Eric Dobmeier	3/4/5	Director	— mixed-class rows	642,825 mixed-class rows	$219,133	—	10 Nov 2023	3/4/5
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.19%	14,000	$200,620	—	30 Sep 2025	13F
Amar Murugan	3/4/5	EVP, Chief Legal Officer	— class O/S missing	26,827	$177,890	—	16 Aug 2024	3/4/5
William K. Heiden	3/4/5	Director	0.31%	22,188	$167,741	—	10 Jun 2025	3/4/5
NORTHERN TRUST CORP	13F	Company	0.15%	11,033	$158,103	—	30 Sep 2025	13F
Matthew K. Fust	3/4/5	Director	0.25%	18,188	$137,501	—	10 Jun 2025	3/4/5
Maria Grazia Roncarolo	3/4/5	Director	0.24%	17,368	$131,302	—	10 Jun 2025	3/4/5
Jill Henrich	3/4/5	EVP, Chief Regulatory Officer	— class O/S missing	18,679	$130,697	—	03 Mar 2025	3/4/5
Ameet Mallik	3/4/5	Director	0.23%	16,928	$127,975	—	10 Jun 2025	3/4/5
Jakob Dupont	3/4/5	EVP, Head of R&D	— mixed-class rows	608,781 mixed-class rows	$113,119	—	02 Mar 2023	3/4/5
Charlene A. Banard	3/4/5	EVP, Chief Technical Officer	— class O/S missing	276,010	$107,368	—	16 May 2023	3/4/5
BANK OF AMERICA CORP /DE/	13F	Company	0.08%	5,845	$83,758	—	30 Sep 2025	13F
Utpal Koppikar	3/4/5	Chief Financial Officer	— class O/S missing	181,978	$70,789	—	02 Mar 2023	3/4/5
Kristin Yarema	3/4/5	Chief Commercial Officer	— mixed-class rows	257,007 mixed-class rows	$66,680	—	01 Mar 2022	3/4/5
Manher Joshi	3/4/5	EVP, Chief Medical Officer	— class O/S missing	171,284	$66,629	—	16 Nov 2023	3/4/5
Beth C. Seidenberg	3/4/5	Director	— mixed-class rows	195,386 mixed-class rows	$45,080	—	31 May 2023	3/4/5
Joe Newell	3/4/5	Chief Operations Officer	— mixed-class rows	123,014 mixed-class rows	$43,995	—	16 Nov 2021	3/4/5
SBI Securities Co., Ltd.	13F	Company	0.02%	1,404	$20,119	—	30 Sep 2025	13F
ROYAL BANK OF CANADA	13F	Company	0.02%	1,209	$17,000	—	30 Sep 2025	13F
Roy D. Baynes	3/4/5	Director	— mixed-class rows	75,000 mixed-class rows	$16,922	—	23 Jun 2022	3/4/5
Private Wealth Asset Management, LLC	13F	Company	0.01%	900	$12,897	—	30 Sep 2025	13F
Ronald C. Renaud Jr.	3/4/5	Director	— mixed-class rows	63,000 mixed-class rows	$12,254	—	23 Jun 2022	3/4/5
JONES FINANCIAL COMPANIES LLLP	13F	Company	0.01%	703	$9,659	—	30 Sep 2025	13F
Tower Research Capital LLC (TRC)	13F	Company	0%	342	$4,901	—	30 Sep 2025	13F
WELLS FARGO & COMPANY/MN	13F	Company	0%	251	$3,597	—	30 Sep 2025	13F
JPMORGAN CHASE & CO	13F	Company	0%	216	$3,095	—	30 Sep 2025	13F

Institutional Holders of Atara Biotherapeutics, Inc. - Common Stock (ATRA) as of Q4 2025

As of 31 Dec 2025, Atara Biotherapeutics, Inc. - Common Stock (ATRA) was held by 40 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 2,049,655 shares. The largest 10 holders included EcoR1 Capital, LLC, Redmile Group, LLC, VANGUARD GROUP INC, MARSHALL WACE, LLP, GLOBEFLEX CAPITAL L P, BlackRock, Inc., GEODE CAPITAL MANAGEMENT, LLC, MACKENZIE FINANCIAL CORP, ACADIAN ASSET MANAGEMENT LLC, and STALEY CAPITAL ADVISERS INC. This page lists 40 institutional shareholders reporting positions in this security for the Q4 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders

Q4 2025 holders

Holder diff

Investor	Q3 2025 Shares	Q4 2025 Shares	Share Diff	Share Chg %	Q3 2025 Value $	Q4 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.